123 related articles for article (PubMed ID: 36868123)
1. Neutrophil-to-Lymphocyte Ratio Is Associated With the Proportion of Poorly Differentiated Components in Papillary Thyroid Carcinoma.
Oba T; Maeno K; Kiyosawa N; Morikawa H; Amitani M; Chino T; Shimizu T; Ono M; Ito T; Kanai T; Uehara T; Ito KI
J Surg Res; 2023 Jul; 287():47-54. PubMed ID: 36868123
[TBL] [Abstract][Full Text] [Related]
2. Does preoperative neutrophil lymphocyte ratio predict risk of recurrence and occult central nodal metastasis in papillary thyroid carcinoma?
Lang BH; Ng CP; Au KB; Wong KP; Wong KK; Wan KY
World J Surg; 2014 Oct; 38(10):2605-12. PubMed ID: 24809487
[TBL] [Abstract][Full Text] [Related]
3. May the neutrophil/lymphocyte ratio be a predictor in the differentiation of different thyroid disorders?
Kocer D; Karakukcu C; Karaman H; Gokay F; Bayram F
Asian Pac J Cancer Prev; 2015; 16(9):3875-9. PubMed ID: 25987053
[TBL] [Abstract][Full Text] [Related]
4. Papillary Thyroid Carcinoma with High-Grade Features Versus Poorly Differentiated Thyroid Carcinoma: An Analysis of Clinicopathologic and Molecular Features and Outcome.
Wong KS; Dong F; Telatar M; Lorch JH; Alexander EK; Marqusee E; Cho NL; Nehs MA; Doherty GM; Afkhami M; Barletta JA
Thyroid; 2021 Jun; 31(6):933-940. PubMed ID: 33143568
[No Abstract] [Full Text] [Related]
5. Prognostic significance of neutrophil-to-lymphocyte ratio for long-term outcomes in patients with poorly differentiated thyroid cancer.
Oba T; Maeno K; Amitani M; Shimizu T; Ohno K; Ono M; Ito T; Kanai T; Uehara T; Ito KI
Endocr J; 2021 Nov; 68(11):1329-1336. PubMed ID: 34219074
[TBL] [Abstract][Full Text] [Related]
6. The Neutrophil-to-Lymphocyte Ratio Correlates with Age in Patients with Papillary Thyroid Carcinoma.
Liu J; Du J; Fan J; Liu K; Zhang B; Wang S; Wang W; Wang Z; Cai Y; Li C; Yu T; Zhu G; Chen J; Li C
ORL J Otorhinolaryngol Relat Spec; 2015; 77(2):109-16. PubMed ID: 25896501
[TBL] [Abstract][Full Text] [Related]
7. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the correlation of neutrophil/lymphocyte ratio with prognostic classification systems in papillary thyroid carcinoma patients.
Yildiz EO; Işcen K; Kaya F; Güney OA; Ulukent SC
Medicine (Baltimore); 2024 Feb; 103(5):e37210. PubMed ID: 38306518
[TBL] [Abstract][Full Text] [Related]
9. The neutrophil to lymphocyte ratio can discriminate anaplastic thyroid cancer against poorly or well differentiated cancer.
Cho JS; Park MH; Ryu YJ; Yoon JH
Ann Surg Treat Res; 2015 Apr; 88(4):187-92. PubMed ID: 25844352
[TBL] [Abstract][Full Text] [Related]
10. Prognostic importance of baseline neutrophil to lymphocyte ratio in patients with advanced papillary thyroid carcinomas.
Kim JY; Park T; Jeong SH; Jeong CY; Ju YT; Lee YJ; Hong SC; Ha WS; Choi SK; Jung EJ
Endocrine; 2014 Aug; 46(3):526-31. PubMed ID: 24272600
[TBL] [Abstract][Full Text] [Related]
11. Case Report: A New Entity: Multiple Differentiated Variant of Papillary Thyroid Carcinoma With Advanced Clinical Behavior.
Yang J; Gong R; Ma Y; Gao J; Li Z; Zhu J; Gong Y
Front Endocrinol (Lausanne); 2021; 12():654638. PubMed ID: 33897621
[TBL] [Abstract][Full Text] [Related]
12. Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) may be superior to C-reactive protein (CRP) for predicting the occurrence of differentiated thyroid cancer.
Ozmen S; Timur O; Calik I; Altinkaynak K; Simsek E; Gozcu H; Arslan A; Carlioglu A
Endocr Regul; 2017 Jul; 51(3):131-136. PubMed ID: 28858848
[TBL] [Abstract][Full Text] [Related]
13. De-differentiation of papillary thyroid carcinoma into squamous cell carcinoma in an elderly patient: A case report.
Thewjitcharoen Y; Krittiyawong S; Butadej S; Nakasatien S; Polchart S; Junyangdikul P; Kanchanapituk A; Himathongkam T
Medicine (Baltimore); 2020 Apr; 99(16):e19892. PubMed ID: 32312017
[TBL] [Abstract][Full Text] [Related]
14. Significance of multifocality in papillary thyroid carcinoma.
Feng JW; Qu Z; Qin AC; Pan H; Ye J; Jiang Y
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1820-1828. PubMed ID: 32732090
[TBL] [Abstract][Full Text] [Related]
15. Re-evaluation of histopathological factors affecting prognosis of differentiated thyroid carcinoma in an iodine-sufficient country.
Sugitani I; Toda K; Yamamoto N; Sakamoto A; Fujimoto Y
World J Surg; 2010 Jun; 34(6):1265-73. PubMed ID: 19953247
[TBL] [Abstract][Full Text] [Related]
16. Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma.
Jung TS; Kim TY; Kim KW; Oh YL; Park DJ; Cho BY; Shong YK; Kim WB; Park YJ; Jung JH; Chung JH
Endocr J; 2007 Apr; 54(2):265-74. PubMed ID: 17379963
[TBL] [Abstract][Full Text] [Related]
17. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma.
Schwertheim S; Sheu SY; Worm K; Grabellus F; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):475-81. PubMed ID: 19370508
[TBL] [Abstract][Full Text] [Related]
18. Relationship Between Serum Inflammatory Factor Levels and Differentiated Thyroid Carcinoma.
Zhang X; Li S; Wang J; Liu F; Zhao Y
Technol Cancer Res Treat; 2021; 20():1533033821990055. PubMed ID: 33752541
[TBL] [Abstract][Full Text] [Related]
19. Long-term outcome of differentiated thyroid carcinoma: experience in a developing country.
Bhargav PR; Mishra A; Agarwal G; Agarwal A; Pradhan PK; Gambhir S; Verma AK; Mishra SK
World J Surg; 2010 Jan; 34(1):40-7. PubMed ID: 20020292
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Mean Platelet Volume, Platelet Count, Neutrophil/ Lymphocyte Ratio and Platelet/Lymphocyte Ratio in the Euthyroid, Overt Hypothyroid and Subclinical Hyperthyroid Phases of Papillary Thyroid Carcinoma.
Kutluturk F; Gul SS; Sahin S; Tasliyurt T
Endocr Metab Immune Disord Drug Targets; 2019; 19(6):859-865. PubMed ID: 30727930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
